Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter studyArticle Published on 2022-09-012022-11-15 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Acetate anti-CD20 antibody Asymptomatic B-cell Course Disease-modifying therapy expected fumarate group healthy healthy control Heterologous homologous humoral Humoral response immune response Interferon-beta mAb majority median Mild multicenter Multiple multiple sclerosis Patient patients Probability Protective reached receiving reduced reported revaccination SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection Seroconversion significantly significantly lower study enrollment therapy Third U/mL vaccination was measured while [DOI] 10.1016/j.msard.2022.104009 PMC 바로가기
Retinal microvascular morphology versus COVID-19: What to anticipate?Research article Published on 2022-09-012022-10-05 Journal: Photodiagnosis and photodynamic therapy [Category] COVID19(2023년), SARS, 바이오마커, 변종, [키워드] age angiotensin-converting enzyme 2 complete recovery COVID-19 COVID-19 infected patient COVID-19 infection cross-sectional Diagnosis eyes Foveal avascular zone group healthy subject healthy subjects Microvascular morphology morphological change morphology no significant difference Optical coherence tomography Optical coherence tomography angiography outer retina parameter parameters pathogenic mechanism patients positive recorded Region Result Retina Retinal SARS-COV-2 infection significant changes in significant difference significantly lower subjects swab sample thrombotic vessel Vessel density [DOI] 10.1016/j.pdpdt.2022.102920 [Article Type] Research article
Early reduction of estimated Glomerular Filtration Rate (eGFR) predicts poor outcome in acutely ill hospitalized COVID-19 patients firstly admitted to medical regular wards (eGFR-COV19 study)Research article Published on 2022-09-012022-10-05 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 바이오마커, [키워드] Acute kidney injury Admission age Analysis analyzed ARDS association AUC Autopsy baseline value calculated Chronic kidney disease correlated COVID-19 creatinine diagnosed died discharge division Efficacy GFR glomerular filtration rate hospital Hospital admission hospital discharge hospitalized COVID-19 patient hospitalized patient ICU identify IL-6 IMV In-hospital death in-hospital mortality Infection intensive care internal Invasive mechanical ventilation KDIGO AKI kidney Kidney injury mechanical ventilation Medicine NIV non-invasive ventilation outcome Patient patients patients’ medical record predict Predictive Primary outcome Prognosis Rate reduction renal dysfunction renal function representing Result SARS-CoV-2 score Secondary outcomes Serum level significantly significantly lower statistical analysis symptomatic Symptoms tissue were assessed with COVID-19 [DOI] 10.1016/j.biopha.2022.113454 [Article Type] Research article
Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home CohortArticle Published on 2022-09-012022-11-15 Journal: JAMA Network Open [Category] SARS, 변종, 진단, [키워드] 95% CI absorbance Ad26.COV2.S age Analysis Anti-RBD IgG antibody antibody level Antibody Response association binding domain blood sample BNT162b2 booster booster doses Breakthrough infection calculated calibrator COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional Delta demonstrated effective home Humoral immunity IgG IgG level increased risk individual Infection Level median multivariate no difference Nursing omicron outcome participant persistence populations Potential protective role regression modeling RNA-1273 SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 surveillance SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant Sex significantly higher significantly lower specimen subsequent the mean vaccination Vaccine Virginia were assessed West white [DOI] 10.1001/jamanetworkopen.2022.31334 PMC 바로가기
Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational studyArticle Published on 2022-09-012022-11-15 Journal: São Paulo medical journal = Revista paulista de medicina [Category] 진단, 치료기술, [키워드] Admission age Analysis analyzed C-reactive protein (CRP Chest Clinical characteristics Comparative conducted Coronavirus disease 2019 COVID-19 COVID-19 patient CRP CRP level CRS Cytokine release syndrome database died disease evaluate ferritin high mortality hospital Hospitalized IL-6 independent risk factor information interleukin-6 laboratory parameter Logistic regression analysis lymphocyte Mortality neutrophil no difference oxygen saturation Patient performed receiving Research retrospective severe COVID-19 patient Signal transduction significantly lower suppresse survival group survived the patient Tocilizumab tocilizumab administration treated Treatment Turkey WBC White blood cell [DOI] 10.1590/1516-3180.2021.0604.R1.23112021 PMC 바로가기
Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant코로나19 델타 변이형 환자에서 카시리비맙-임데비맙 항체 병용요법의 임상적 효능Article Published on 2022-09-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus 2 administration age antibody cocktail antibody combination antibody treatment Casirivimab Casirivimab-imdevimab treatment clinical Clinical efficacy cocktail Combination conducted control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death Delta delta variant dose Efficacy evaluate FIVE High flow nasal cannula high-risk patient High-risk patients hospital Hospitalization Imdevimab inclusion criteria intravenously Japan mechanical ventilation monoclonal antibodies monoclonal antibody nasal nasal cannula Neutralizing antibodies outcome oxygen Oxygen therapy Patient patients with COVID-19 receive reduce reduced respiratory risk SARS-CoV-2 significantly lower therapy Treatment treatment group Viral Viral load with COVID-19 [DOI] 10.1016/j.jiac.2022.05.012 PMC 바로가기 [Article Type] Article
Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN SurveyResearch article Published on 2022-09-012022-10-05 Journal: Pharmacological research [Category] 바이오마커, [키워드] Administered ascorbic acid Borg Combination COVID-19 Critical Effect effort Endothelial dysfunction endothelial function Evidence favorable effect IMPROVE in both groups indicate L-Arginine long-COVID oxidative stress pathophysiology Patient receiving recent reduce Result significant difference significantly lower survey Symptom Symptoms Treatment treatment arm two groups typical symptom Vitamin Vitamin C [DOI] 10.1016/j.phrs.2022.106360 [Article Type] Research article
Evaluation of water gargle samples for SARS-CoV-2 detection using Abbott ID NOW COVID-19 assayAbbott ID NOW COVID-19 분석을 사용한 SARS-CoV-2 검출을 위한 양치질 샘플 평가Article Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료기술, [키워드] 95% CI 95% confidence interval Abbott Abbott ID NOW acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 added addition amplification asymptomatic patient asymptomatic patients Chain Reaction compatible symptoms Coronavirus-2 COVID-19 cycle threshold evaluate gargle NAAT Nasal sample nasopharyngeal noninvasive nucleic acid nucleic acid amplification test Patient pipette polymerase chain reaction positive positive sample Randomly residual Reverse transcription-polymerase chain reaction RT-PCR SARS-CoV-2 SARS-CoV-2 detection SARS-COV-2 infection selected Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus shown significantly lower specimen Standard of care symptomatic patient Symptomatic patients water [DOI] 10.1002/jmv.27847 PMC 바로가기 [Article Type] Article
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019Article Published on 2022-09-012022-11-15 Journal: Mayo Clinic proceedings [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Admission B.1.617.2 Care clinical Clinical outcome Cohort comparable coronavirus disease COVID-19 COVID-19 vaccination death Delta high-risk patient Hospitalization intensive care large cohort Mild moderate Moderate COVID-19 Mortality outcome oxygen supplementation Patient patients treated Rate Respiratory Coronavirus Retrospective study SARS-CoV-2 severe disease significantly lower Sotrovimab the SARS-CoV-2 Treatment were assessed [DOI] 10.1016/j.mayocp.2022.06.015 PMC 바로가기
Rates of COVID-19 infection among in vitro fertilization patients undergoing treatment at a university reproductive health centerArticle Published on 2022-09-012022-11-16 Journal: Journal of Assisted Reproduction and Genetics [Category] 변종, [키워드] Asymptomatic COVID-19 caused Cohort coronavirus disease COVID-19 COVID-19 infection COVID-19 testing demonstrated determine evaluate evaluated female Future Gynecology health center in vitro In-vitro incidence of COVID-19 Infection infertility knowledge Los Angeles material Patient patient population patients PCR polymerase chain Positive test positive test result Rate representing reproductive Retrospective study significantly lower surgery Surgical Procedure Treatment vaccination rates variant [DOI] 10.1007/s10815-022-02581-2 PMC 바로가기